The Relationship of  Obesity – Cholesterol – Triglycerides  to Metabolic Syndrome:  Assessment and Interventions Presented...
The Relationship of Obesity-Cholesterol-Triglycerides to Metabolic Syndrome <ul><li>Accumulating scientific research has s...
The Relationship of Obesity-Cholesterol-Triglycerides to Metabolic Syndrome <ul><li>Adipose tissue plays an important role...
The Relationship of Obesity-Cholesterol-Triglycerides to Metabolic Syndrome <ul><li>Macrophage accumulation in adipose tis...
The Relationship of Obesity-Cholesterol-Triglycerides to Metabolic Syndrome <ul><li>Liposuction of abdominal subcutaneous ...
Prevalence of CAD Risk Factors
Parallels
Relative Risk of CAD Mortality
Metabolic Syndrome
Associations
Mechanisms of Dyslipidemia
The Relationship of Obesity-Cholesterol-Triglycerides to Metabolic Syndrome <ul><li>ASSESSMENT </li></ul><ul><ul><ul><ul><...
Patient Overview     AVERAGE MIN MAX Age   51.8 28 73 Married   139 total     Children   2.4 0 15           Ht   70.8 60.4...
What is IMT? <ul><li>IMT measured the Intima-Media Thickness (IMT) of the common carotid </li></ul><ul><ul><li>Determines ...
The Relationship of Obesity-Cholesterol-Triglycerides to Metabolic Syndrome <ul><li>INTERVENTION </li></ul><ul><ul><ul><ul...
Exhaustive, Scholarly Work
Eukaryotes
Paleolithic Nutrition A Consideration of Its Nature and Current Implications S. Boyd Eaton, MD, and Melvin Konner, PhD NEJ...
Ancestral vs. Modern Humans
The Relationship of Obesity-Cholesterol-Triglycerides to Metabolic Syndrome <ul><li>PHARMACEUTICALS </li></ul><ul><ul><ul>...
Potential Mechanisms
The Relationship of Obesity-Cholesterol-Triglycerides to Metabolic Syndrome <ul><li>PHARMACEUTICALS, cont’d </li></ul><ul>...
Hypothetical Model
Multisite Location
Effects
Upcoming SlideShare
Loading in...5
×

Simpson edited version

415

Published on

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
415
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Simpson edited version

  1. 1. The Relationship of Obesity – Cholesterol – Triglycerides to Metabolic Syndrome: Assessment and Interventions Presented by Graham Simpson, MD Institute Physician, Cenegenics ® Medical Institute
  2. 2. The Relationship of Obesity-Cholesterol-Triglycerides to Metabolic Syndrome <ul><li>Accumulating scientific research has shown that adipose tissue is an active endocrine and metabolic organ that plays a critical role in the development of cardiometabolic risk factors, diabetes and cardiovascular disease. </li></ul>
  3. 3. The Relationship of Obesity-Cholesterol-Triglycerides to Metabolic Syndrome <ul><li>Adipose tissue plays an important role in the development of low-grade systemic inflammation. Adipose tissue secretes a number of cytokines TNF2, IL1, IL6, adiponectin, leptin, plasminogen activator-1 – these stimulate inflammatory protein production in the liver through activation of NFKB. </li></ul>
  4. 4. The Relationship of Obesity-Cholesterol-Triglycerides to Metabolic Syndrome <ul><li>Macrophage accumulation in adipose tissue also promotes obesity associated inflammation and its sequelae, including endothelial dysfunction, insulin resistance, dyslipidemia, hypertension, impaired thrombolysis, diabetes and atherosclerosis. </li></ul>
  5. 5. The Relationship of Obesity-Cholesterol-Triglycerides to Metabolic Syndrome <ul><li>Liposuction of abdominal subcutaneous adipose tissue has been shown not to improve cardiometabolic risk factors, whereas experimental studies report that reduction of visceral fat improved glucose levels and insulin sensitivity. </li></ul>
  6. 6. Prevalence of CAD Risk Factors
  7. 7. Parallels
  8. 8. Relative Risk of CAD Mortality
  9. 9. Metabolic Syndrome
  10. 10. Associations
  11. 11. Mechanisms of Dyslipidemia
  12. 12. The Relationship of Obesity-Cholesterol-Triglycerides to Metabolic Syndrome <ul><li>ASSESSMENT </li></ul><ul><ul><ul><ul><li>Blood tests </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Tape measure </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Dexa scan </li></ul></ul></ul></ul><ul><ul><ul><ul><li>IMT </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Vascular reactivity (FMD) </li></ul></ul></ul></ul>
  13. 13. Patient Overview     AVERAGE MIN MAX Age   51.8 28 73 Married   139 total     Children   2.4 0 15           Ht   70.8 60.4 78.8 Wt   212.7 134 344.5 % body fat   30.3 9.2 44.2 Densitometer   none = 95 Penia = 83 Porosis = 20 Depression   8.3 0 32 QLI   6.6 0 22           Glucose   95.3 65 245 A1C   5.6 4.6 11.2 M Gluc   123.2 86 321 F Insulin   7.6 1 59 Uric Acid   6.6 1.6 11.8 Homo   9.9 3.8 20.5 CRP   3.0 0.1 37.8           Chol   197.5 109 331 TG   151.4 39 975 HDL   49.7 31 99 LDL   121.3 40 235           Total Test   428.6 29 966 Free Test   67.2 5.6 936 DHT   37.8 2 182 E2   23.7 1 158 IGF   159.8 66 315 PSA   1.2 0.1 5.3 DHEA   163.5 2.5 1210 TSH   2.42 0.7 12.66
  14. 14.
  15. 15. What is IMT? <ul><li>IMT measured the Intima-Media Thickness (IMT) of the common carotid </li></ul><ul><ul><li>Determines the presence and severity of atherosclerosis </li></ul></ul><ul><li>IMT of the carotid artery has been conclusively demonstrated as a surrogate endpoint for cardiovascular disease (CVD) </li></ul><ul><li>IMT evaluates CVD itself instead of the risk factors for the disease </li></ul>
  16. 16. The Relationship of Obesity-Cholesterol-Triglycerides to Metabolic Syndrome <ul><li>INTERVENTION </li></ul><ul><ul><ul><ul><ul><li>Lifestyle </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><ul><li> Paleo-Nutrition </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><ul><li> Nutraceuticals </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><ul><li> Exercise </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><ul><li> Detoxification </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><ul><li> Mind-Body Rx </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>Hormone Restoration </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>Pharmaceuticals </li></ul></ul></ul></ul></ul>
  17. 17. Exhaustive, Scholarly Work
  18. 18. Eukaryotes
  19. 19. Paleolithic Nutrition A Consideration of Its Nature and Current Implications S. Boyd Eaton, MD, and Melvin Konner, PhD NEJM 31Jan85 Vol 312 No.5
  20. 20. Ancestral vs. Modern Humans
  21. 21. The Relationship of Obesity-Cholesterol-Triglycerides to Metabolic Syndrome <ul><li>PHARMACEUTICALS </li></ul><ul><ul><ul><ul><li>Metformin </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Orlistat </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Niacin </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Statins </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Omega 3 fatty acids </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Fibrates </li></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>Gemfibrozil </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>Fenofibrate </li></ul></ul></ul></ul></ul>
  22. 22. Potential Mechanisms
  23. 23. The Relationship of Obesity-Cholesterol-Triglycerides to Metabolic Syndrome <ul><li>PHARMACEUTICALS, cont’d </li></ul><ul><ul><ul><ul><li>Cholesteryl Ester Transfer Protein Inhibitor (CETP) </li></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>Torcetrapib (discontinued) </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>JTT-705 </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><li>Endocannabinoid Receptor Antagonism </li></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>Rimonabant (first CB1 antagonist) </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><li>Thiazolidinediones </li></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>Pioglitazone </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><li>Obesity Drugs </li></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>Sibutramine (Meridia) </li></ul></ul></ul></ul></ul>
  24. 24. Hypothetical Model
  25. 25. Multisite Location
  26. 26. Effects
  1. A particular slide catching your eye?

    Clipping is a handy way to collect important slides you want to go back to later.

×